Skip to content

Exploring the Therapeutic Effect and Mechanism of Myofascial Trigger Points Theory in Primary Dysmenorrhea

Myofascial trigger point in the treatment of primary dysmenorrhea and neuromuscular mechanism - Exploring the Therapeutic Effect and Mechanism of Myofascial Trigger Points Theory in Primary Dysmenorrhea

Status
Unknown
Phases
Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2400092346
Enrollment
Unknown
Registered
2024-11-14
Start date
2023-04-02
Completion date
Unknown
Last updated
2025-12-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

primary dysmenorrhea

Interventions

Myofascial Trigger Point Treatment Group:The myofascial trigger point group consisted of a treatment conducted by a doctor with extensive clinical experience in treating myofascial pain and using myof
? deep palpation of the tender point could induce distant referred pain. Seven pairs of trigger points potentially related to dysmenorrhea were identified: four pairs on the rectus abdominis, one pair
control group:Subjects in the control group did not receive treatment for myofascial trigger points during their vacation period, and painkillers were used when the pain was really extreme.

Sponsors

Shanghai Yangpu District Central Hospital (Tongji University Affiliated Yangpu Hospital)
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 35 Years

Inclusion criteria

Inclusion criteria: 1.Those who meet the above diagnostic criteria for PDM; 2.Aged between 18-35 years old; 3. Those with a VAS score of 4 or more; 4. Those who have regular menstrual cycles; 5. Those who have not taken any pain-relieving drugs within 1 month before treatment; 6.Willing to accept abdominal acupuncture treatment and willing to cooperate in completing the relevant procedures of this experiment.

Exclusion criteria

Exclusion criteria: 1.Diagnosis of secondary dysmenorrhea, or the presence of organic pathologies such as pelvic inflammatory disease, endometriosis, uterine fibroids, etc; 2.Combination of serious primary diseases such as liver, kidney, hematopoietic system, cardiovascular system, or mental illness; 3.Concurrently receiving other treatments related to the treatment of this disease; 4.Infection of the skin at the trigger point site and abnormal coagulation function; 5.Others: not treated according to the provisions of this clinical trial, withdrawing halfway, etc

Design outcomes

Secondary

MeasureTime frame
intra-abdominal pressure;Pressure Pain Threshold;two-point discrimination;point-to-point test;two point estimation;Muscle Structure and Morphology;Surface Electromyographic (sEMG) Signals of Abdominal Muscles;Skin Conductance;Skin Temperature;Heart Rate;

Primary

MeasureTime frame
Visual Analogue Scale for Pain;Short-Form McGill Pain Questionnaire , SF-MPQ;

Countries

China

Contacts

Public ContactXingli Chen

Shanghai Yangpu District Central Hospital (Tongji University Affiliated Yangpu Hospital)

dsnever@163.com+86 155 5055 9812

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026